Mohamed H. Ladha
Mohamed H. Ladha
About
Detail
Bridgewater, New Jersey, United States
Mohamed Ladha is a C-suite/CEO/President caliber biopharma executive with more than 25 years of experience leading enterprise and commercial organizations across rare diseases, oncology, hematology and specialty care markets.
He has built and scaled fully integrated businesses, led 16 US and global launches & commercialization across biologics, biosimilars, drug conjugates, and small molecules, and delivered sustained value creation across North America, Europe, Japan, and emerging markets.
Recordati Rare Diseases — President & GM, North America
• Led Recordati’s largest affiliate: a 350+ person fully integrated organization across the U.S. and Canada.
• Held full P&L accountability for a nine product portfolio projected to exceed $750M in 2026 revenue.
• Scaled the business from ~$220M (2021) to ~$600M (2025).
• Delivered 39% year over year growth in Q1 2026.
Career Leadership & Impact
• Senior leadership roles at Oncopeptides, Tocagen, Takeda Oncology, Pfizer, and Merck.
• Built and led high performing commercial, medical and enterprise organizations across rare disease, oncology, and specialty markets.
• Led 16+ global product launches, including Sylatron, ALUNBRIG, PEPAXTO, Retacrit, and Inflectra.
• Managed a $700M+ oncology portfolio at Merck and contributed to the advancement of pembrolizumab into pivotal studies.
Mohamed also brings significant transaction and enterprise building experience, including eight in licensing transactions, four acquisitions, and negotiations representing more than $5B in aggregate deal value. He has raised more than $300M in capital, co led multiple commercial/enterprise integrations, and supported licensing involving mRNA and CAR T platforms.
He holds an MBA from Northwestern University’s Kellogg School of Management, an MPA from Harvard Kennedy School, and a BA from Hampshire College. His early oncology research experience at Dana Farber complements his scientific fluency and strategic judgment.
He has built and scaled fully integrated businesses, led 16 US and global launches & commercialization across biologics, biosimilars, drug conjugates, and small molecules, and delivered sustained value creation across North America, Europe, Japan, and emerging markets.
Recordati Rare Diseases — President & GM, North America
• Led Recordati’s largest affiliate: a 350+ person fully integrated organization across the U.S. and Canada.
• Held full P&L accountability for a nine product portfolio projected to exceed $750M in 2026 revenue.
• Scaled the business from ~$220M (2021) to ~$600M (2025).
• Delivered 39% year over year growth in Q1 2026.
Career Leadership & Impact
• Senior leadership roles at Oncopeptides, Tocagen, Takeda Oncology, Pfizer, and Merck.
• Built and led high performing commercial, medical and enterprise organizations across rare disease, oncology, and specialty markets.
• Led 16+ global product launches, including Sylatron, ALUNBRIG, PEPAXTO, Retacrit, and Inflectra.
• Managed a $700M+ oncology portfolio at Merck and contributed to the advancement of pembrolizumab into pivotal studies.
Mohamed also brings significant transaction and enterprise building experience, including eight in licensing transactions, four acquisitions, and negotiations representing more than $5B in aggregate deal value. He has raised more than $300M in capital, co led multiple commercial/enterprise integrations, and supported licensing involving mRNA and CAR T platforms.
He holds an MBA from Northwestern University’s Kellogg School of Management, an MPA from Harvard Kennedy School, and a BA from Hampshire College. His early oncology research experience at Dana Farber complements his scientific fluency and strategic judgment.
Contact Mohamed regarding:
work
Full-time jobs